Antihypertensive treatment in critical limb ischaemia

Anders Gottsäter, Peter M. Nilsson
University of Lund, Department of Vascular Diseases, Skåne University Hospital

Abstract
Peripheral artery disease (PAD) is defined as atherosclerotic arterial occlusive disease of the lower extremities, manifesting as intermittent claudication (IC, pain induced by walking) or critical limb ischaemia (CLI, rest pain or ulcerations). PAD guidelines recommend strict control of cardiovascular risk factors, and European guidelines on hypertension recommend a blood pressure (BP) target < 140/90 mm Hg also in PAD patients. As the pressure in the affected extremity might be of relevance for the prognosis concerning limb salvage in CLI, the traditional approach was to avoid beta-blockers and allow a slightly higher BP in CLI. Both theoretical considerations and observational data support aggressive BP lowering also in CLI; however, in the absence of randomized studies on BP lowering in this setting it cannot be definitely established that current recommendations on BP lowering apply also in CLI.

key words: peripheral artery disease, critical limb ischaemia, blood pressure

DOI: 10.5603/AH.2016.0020

Hypertension in peripheral arterial disease
Peripheral artery disease (PAD) is defined as atherosclerotic arterial occlusive disease of the lower extremities. PAD can manifest as intermittent claudication (IC, pain induced by walking) or critical limb ischaemia (CLI, rest pain or ulceration for more than 14 days) [1]. PAD affected 202 million people worldwide in 2010 [2, 3], and in a database of over 9 million patients, PAD prevalence was 10.7% [4]. Furthermore, PAD patients have a high frequency of concomitant atherosclerotic disease, and risk factors for atherosclerosis such as arterial hypertension are common in this population [5, 6]. Major PAD guidelines issued by ACC/AHA [7] and TASC [1], recommend strict control of cardiovascular risk factors in this group of patients, and the current European guidelines on treatment of hypertension recommend a blood pressure (BP) target of less than 140/90 mm Hg also in PAD patients [8].

Prior concerns on blood pressure treatment and beta-blocker use in IC patients have been offset by meta-analyses from the Cochrane Collaboration [9–11]. This work has confirmed that the benefits of treating hypertension in PAD patients are overwhelming, whereas there is no clear evidence that any antihypertensive drug class confers specific benefits in relation to another [9–11]. The vast majority of patients in the studies in the above meta-analyses have, however, been included in studies with a diagnosis of IC. Patients with CLI represent about 1% of the total number of PAD patients [1], and as this condition is scientifically defined as chronic ischaemic rest pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease (ankle pressure of < 50–70 mm Hg, or toe pressure of < 30–50 mm Hg, or TCPO₂ < 30–50 mm Hg) [1],
inclusion and follow-up of these patients in scientific studies of blood pressure lowering is complicated. Therefore, most review authors do not address this group specifically.

**Antihypertensive treatment in critical limb ischaemia**

Furthermore, blood pressure might have other relevance in CLI than as a risk factor for cardiovascular disease. As the pressure in the affected extremity might be of relevance for the prognosis concerning limb salvage, the traditional approach was to avoid beta-blockers and allow a slightly higher blood pressure in this setting [12]. Additionally, the concept of increasing blood pressure and thereby increasing collateral circulation in an ischaemic extremity seems intuitively appealing. Regional hyperperfusion via extracorporeal limb perfusion has been evaluated in CLI with promising results [13], and benefits of sequential pneumatic compression have been suggested in prevention of minor amputation, prolonging amputation-free survival, and improving rest pain in patients with non-reconstructable CLI [14].

Many factors would theoretically support a benefit of aggressive blood pressure lowering also in CLI, however. High frequencies of concomitant coronary heart disease [15, 16] congestive heart failure [16–18], and coronary valve disease [19] have been demonstrated in this group. In a necropsy study [16], 92% of patients amputated because of CLI showed advanced coronary atherosclerosis. Five-year cardiovascular mortality in symptomatic PAD in different studies was recently estimated to 13% (CI 9–17%) by Sigvant et al. [20]. In CLI, this figure is higher — around 20% already after one year [21–23] and mainly caused by cardiac disease [21–23].

Blood pressure seems to be of relevance for this outcome. Increased preoperative pulse pressure [24] and uncontrolled hypertension [25] are associated with procedural complications and increased mortality in patients after distal intervention for CLI. In other studies of primary revascularization in CLI patients, lack of beta-blocking therapy has been associated with increased risk of heart related adverse events [26, 27].

**Conclusion**

Although the above observational data from CLI patients supports recommendations on antihypertensive treatment in CLI, it cannot be definitely established that current recommendations on antihypertensive treatment apply also in this group in the absence of randomized studies on blood pressure lowering. Patients with CLI therefore need to be further studied by physicians with knowledge of and interest for treatment of arterial hypertension. As different relationships between blood pressure levels and tissue perfusion might apply in diabetic and non-diabetic patients with limb ischaemia [28, 29], these two groups should preferably be studied separately.

**References**


